Business Context and Reporting Period
This Form 8-K Current Report was filed by LifeStance Health Group, Inc. on May 7, 2026, with the report date reflecting the earliest event reported on that same day. The filing details a secondary offering of common stock involving the Company, J.P. Morgan Securities LLC as the underwriter, and specific selling stockholders.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The transaction described is a secondary offering where the Company did not receive any proceeds. Key transaction details include:
- Shares Offered: 35,000,000 shares of Common Stock.
- Source of Shares: All shares were sold by Selling Stockholders.
- Company Repurchase: The Company agreed to purchase 6,000,000 of the shares sold by the Selling Stockholders at the same price paid by the Underwriter.
- Proceeds to Company: $0 (The Company received no proceeds from the offering).
- Underwriter Compensation: The Underwriter received no compensation for the shares repurchased by the Company.
- Closing Date: May 12, 2026.
Material Changes
The filing reports a material event regarding the capital structure and ownership distribution rather than operational changes. The Company entered into an Underwriting Agreement to facilitate the sale of 35,000,000 shares by existing stockholders. While the Company repurchased 6,000,000 shares from the selling stockholders, this transaction did not generate cash inflow for the Company. The filing text does not provide comparative data to prior periods for financial metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to the Company's operational outlook. The primary disclosure is the execution of the Underwriting Agreement, which is incorporated by reference as Exhibit 1.1. Legal counsel, Ropes & Gray LLP, has issued an opinion regarding the shares sold, filed as Exhibit 5.1.
Investor Verification Checklist
- Verify the identity of the Selling Stockholders named in Schedule II of the Underwriting Agreement to assess potential dilution or insider selling pressure.
- Confirm the final closing price per share, as the filing text states the repurchase price equals the underwriter's purchase price but does not disclose the specific dollar amount.
- Review the full Underwriting Agreement (Exhibit 1.1) for details on lock-up agreements, indemnification, and specific terms of the 6,000,000 share repurchase.
- Check subsequent filings for the impact of the 6,000,000 share repurchase on the Company's cash balance and treasury stock accounts.